



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Badley, R. A. *et al.*

Application No: 10/609,014

Filed: June 27, 2003

Title: *Luminescence Assays and Assay Readers*


Examiner: Snay, J. R.

Art Unit: 1743

Attorney Docket No.: ISA-002.01

**CERTIFICATE OF FIRST CLASS MAILING**

I hereby certify that the foregoing "*Transmittal of Certified Copies of Priority Documents*" is being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 21, 2006.

  
John Barretto

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**BEST AVAILABLE COPY**


**TRANSMITTAL OF CERTIFIED COPIES OF PRIORITY DOCUMENTS**

Examiner Snay:

Enclosed herewith are certified copies of priority documents GB0214881.5 filed on June 27, 2002 and GB0219891.9 filed August 27, 2002, in connection with the above-referenced patent application.

Respectfully submitted,  
FOLEY HOAG LLP

Dated: March 21, 2006  
FOLEY HOAG LLP  
155 Seaport Blvd  
Boston, MA 02210-2600  
Customer No. 25181  
Telephone: (617) 832-1000  
Fax: (617) 832-7000

  
Jennifer A. Zarutskie  
Reg. No. 50,558  
Attorney for Applicants  
Direct Tel.: (617) 832-1754

**THIS PAGE BLANK (USPTO)**



BEST AVAILABLE COPY

**CERTIFIED COPY OF  
PRIORITY DOCUMENT**

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., pl. P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

10 November 2005


**THIS PAGE BLANK (USPTO)**



1/77  
28AUG02 E743 11-7 000009  
P01/7700 0.00-0219891.9  
The Patent Office

# Request for grant of a patent

(See the notes on the back of this form. You must also send an explanatory leaflet from the Patent Office to help you fill in this form)



Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference

GP6088892

2. Patent application number

(The Patent Office will fill in this part)

0219891.9

127 AUG 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)  
Patents ADP number (if you know it)

UNIPATH LIMITED  
PRIORY BUSINESS PARK  
BEDFORD  
MK44 3UP  
UNITED KINGDOM

If the applicant is a corporate body, give the country/state of its incorporation

6820989002  
GB

4. Title of the invention

ASSAY READER

5. Name of your agent (if you have one)

MEWBURN ELLIS

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

YORK HOUSE  
23 KINGSWAY  
LONDON  
WC2B 6HP

Patents ADP number (if you know it)

109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request?

(Answer "Yes" if:

a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant,  
or

c) any named applicant is a corporate body.

See note (d))

YES

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 23

Claim(s) 7

Abstract 0

Drawing(s) 5

10. If you are also filing any of the following, state how many against each item

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents (Please specify) 0

11. I/We request the grant of a patent on the basis of this application.

Signature

*Nicholas Sutcliffe*

Date

27 August 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Nicholas Sutcliffe

01223 420383

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

Assay Reader

5 This invention relates to methods and apparatus for detecting the presence of analyte in a sample, in particular to luminescence-based methods for such detection.

10 The use of luminescence in diagnostic assay systems has led to improvements in both sensitivity and the ability to quantify analyte levels, compared to traditional colour detection methods. A fluorescence-based system, for example, may employ a lamp to provide excitation light to excite a fluorescent label molecule and a  
15 detection system, typically a camera or photodiode, to quantify the emitted light from the fluorescent label. Very low levels of fluorescent label molecules may be detected in this way. Commonly in assay systems, fluorescent label molecules are attached to other  
20 molecules which take part in binding events involving analyte. This allows low levels of analyte to be detected and quantified.

25 A major drawback with the use of fluorescence-based assay systems is the high level of instrumentation required to detect and process the luminescent signal prior to its interpretation by the user. The provision of an excitation source, a photodetector and a processor results in bulky and/or expensive instruments.

30 Visually read qualitative assay systems incorporating coloured labels such as gold sol and blue latex particles provide useful but limited sensitivity. This is primarily due to the inherent insensitivity of light absorption,

which is how colour is detected. Whilst this has allowed the development of rapid user-friendly assay systems for the assessment of analytes such as hCG {human chorionic gonadotrophin} in the urine of pregnant women, there is a  
5 need for more sensitive assays in order to detect other analytes in similar user-friendly formats. Furthermore, improvements in the sensitivity of hCG assays may have significant implications in the detection of pregnancy in an emergency room setting, where the detection of  
10 pregnancy before any outwardly visible signs may directly affect the treatment administered.

The present inventors have discovered that the inherent sensitivity of luminescence may be exploited in a rapid  
15 user-friendly assay format to provide a result which can be visually assessed by the user and which has significantly greater sensitivity than conventional visually read colour-based assays.

20 Aspects of the invention relate to assay readers which allow the direct observation of a luminescent signal on an assay device by the user and are therefore suitable for use in rapid user-friendly assay systems.

25 One aspect of the invention provides an assay reader for determining the presence of a luminescent label in the capture zone of an assay device comprising,

a positioning member to hold the assay device in a reading position,

30 a light source which produces an excitation signal for exciting luminescent label in said capture zone when said assay member is in the reading position, and;

a viewing window for direct observation of the luminescent emission signal from said label in said capture zone.

- 5 A positioning member may be any feature which holds the device in place in or on the reader. Many such features are known in the art. For example, the member may be a clip, or a recess/protrusion which engages a corresponding protrusion/recess on the assay device.

10

A suitable light source may be any lamp or light emitter which produces light of a wavelength suitable to excite the label. Conveniently the source may be an LED. In some embodiments, the light source is an ultra-violet light source, for example an ultra-violet LED such as the  
15 Roithner Lasertechnik RLT370-110 UV emitter or the Toyoda-Gosei E1L5M-3P0AP-02 UV emitter.

- In preferred embodiments, the luminescent label is a  
20 fluorescent label and the emission signal is a fluorescent emission signal.

- A suitable viewing window may be any opening or open region which allows the operator to directly observe the  
25 emission signal from the capture zone of the assay device.

- A capture zone is any region of an assay device in which the presence of luminescent label may be detected and/or  
30 measured to determine the presence of analyte in a sample. Thus in a lateral flow device, the capture zone may be part of a porous matrix which contains capture reagents for immobilising luminescent label. Such reagents may be comprised within one or more binding

regions. Depending on the assay format, the amount of immobilised luminescent label in the capture zone may increase or decrease in the presence of analyte. For example, in a sandwich assay format, the amount of  
5 immobilised label will increase, while in a competition assay format, the amount of immobilised label will decrease.

Alternatively, in a homogenous assay device, the capture  
10 zone may be any portion of an assay solution in which assay reagents bind to analyte to produce an increase or decrease in the amount of label molecule which is available to luminesce in response to excitation. In some embodiments, the capture zone of a homogenous assay  
15 device may thus comprise the entire assay solution.

The light source may be contained in a housing, the housing further containing the assay device when in the reading position,  
20 the viewing window being positioned in the housing so as to provide for direct observation of the emission signal from label in the capture zone of the device.

The window may, for example, comprise an aperture or port  
25 in the housing of the reader or in other embodiments, the housing may define a recess which accommodates the assay device in the reading position, the window comprising the mouth of the recess.

30 Preferably, the wavelength of the excitation signal is different from the wavelength of the emission signal, for example, the wavelength of the excitation signal may be greater than the wavelength of the emission signal, or

the wavelength of the excitation signal may be less than the wavelength of the emission signal.

For labels comprising beta-diketones of europium III (as  
5 used in DELFIA™ system from PerkinElmer Life Sciences), an excitation signal of 350-370nm may be used to elicit an emission signal of 612nm.

For labels comprising fluorscein (Molecular Probes), an  
10 excitation signal of 490nm may be used to elicit an emission signal of 540nm.

For labels comprising up-converting phosphor (Niedbala et  
al Anal. Biochem. 293 22-30 (2001); Uplink system,  
15 Orasure (Pennsylvania)), an excitation signal of about 980nm may be used to elicit an emission signal of 475 or 550nm.

Label in the capture zone may be confined to one or more  
20 discrete binding regions. These binding regions may, for example, take the form of a test line and a control line. The presence of label in the control line indicates that the test is working correctly and the presence of label in the test line indicates that there is analyte in the  
25 sample.

Two or more discrete binding regions may be observed through a single viewing window or through separate multiple viewing windows.

30

A reader may comprise a filter to block the passage of the excitation signal through the viewing window. This prevents visual observation of the emission signal being obscured or swamped by the excitation signal.

Suitable filters include dichroic filters (available, for example, from Optical Coating Laboratory Inc, Santa Rosa, CA) or band pass filters (available, for example, from Edmund Optics, Barrington NJ). In some embodiments, preferred filters may have UV protective properties.

The filter may be located at the viewing window or elsewhere in the reader. In some embodiments, it may be located in the assay device. In such embodiments, the assay device in the reading position may be located between the viewing window and the light source, such that the filter in the device blocks the passage of the excitation signal from the light source to the viewing window.

An assay reader as described herein may be used for determining the presence of a first and a second luminescent label in said capture zone. This may be useful, for example where the first label produces a control signal and the second label produces a signal indicative of the presence of analyte. Alternatively, the presence of two or more different analytes may be determined using the same assay device, a different label producing a signal indicative of each analyte. The reader may also be used to determine the presence of more than two, for example three, four, five, six or more than six labels in the capture zone.

This may be achieved in a number of ways. For example, a reader may comprise a first filter which blocks the passage of the first emission signal, which may for example be a control signal, from the first label and a

second filter which blocks passage of a second emission signal from a second luminescent label.

The first and second filters may be switchable between a  
5 first configuration, in which the first filter is positioned at said viewing window and a second configuration, in which the second filter is positioned at said viewing window. This allows the operator to change the filter to view the different emission signals  
10 in turn (i.e. sequentially).

Alternatively, the first filter may be positioned at a first viewing window and the second filter may be positioned at a second viewing window. This allows the  
15 operator to change the filter to view the different emission signals simultaneously using separate viewing windows.

In another approach, a reader may comprise a first light  
20 source which produces a first excitation signal for exciting the first luminescent label and a second light source which produces a second excitation signal for exciting the second luminescent label.

25 The first and second light sources may be switchable between a first mode, in which the first excitation signal is produced without the second excitation signal, and a second mode, in which the second excitation signal is produced without the first excitation signal. This  
30 allows the operator to observe the first emission signal by operating only the first light source and then to observe the second emission signal by operating only the second light source.

To determine the presence of increased numbers of labels, the number of filters and/or light sources described above may be increased accordingly.

- 5 An assay reader may comprise a light guide which channels the excitation signal from the light source as required to different regions of the capture zone, for example to one or more binding regions such as test and control lines. For example light from a single light source may
- 10 be split and be directed to two or more different regions in controlled proportions. This may increase the strength of the emission signal and improve the accuracy of the results.
- 15 The viewing window may comprise a lens to manipulate the emission signal for observation, i.e. the lens may be shaped so as to adapt the image in the viewing window, for example it may magnify the image in said window.
- 20 The properties of the lens depend on the composition, curvature and design of the lens. A lens may also be used in conjunction with apertures of particular shapes.

- In embodiments in which the assay reader is used to
- 25 determine the presence of a first and a second luminescent label in said capture zone, the emission from the first label may be adapted into a first shape and emission from the second label may be adapted into a second shape. This facilitates the distinction of the
- 30 two signals, one of which may be a control and the other a sample signal, by the operator.

The window may comprise a non-reflective surface to prevent reflected ambient light from impeding observation

of the emission signal. The window may also comprise a screen which allows passage of the emission signal but prevents the entry of external ambient light into the reader.

5

The light source may be powered by a power source such as a battery connected thereto. Suitable batteries include lithium and alkaline batteries. The reader may comprise circuitry which is adapted to power the light source in the presence of liquid in said assay device. Suitable circuitry may include electrodes to contact the assay device in the reading position.

The reader may also comprise circuitry which provides a fixed current from said battery. This prevents inaccurate or false readings caused by low battery charge. An example of suitable circuitry is shown in Figure 5. In this example, two diodes (D1, D2) are fed from resistor (R1) and develop a constant voltage of 2V (approx.) regardless of battery voltage. This voltage is connected to the base of transistor (T1). The constant base emitter drop of 0.7V ensures that a fixed voltage of 1.3V (approx.) appears across resistor (R2). This sets the current flowing out of the emitter of the transistor (T1) at a fixed level. The current flowing into the connector is approximately equal to the emitter current, and hence the current through the light emitting diode (D3) is fixed at this level.

To ensure that the reader is working properly before taking a reading, an assay reader may comprise a control indicator to indicate the generation of the excitation signal.

Suitable control indicators may include an LED, electrochromic or thermochromic indicator. Such an indicator may be positioned on an outer surface of said reader or within the housing such that the indicator is visible through a control window. Alternatively, fluorescent dye may be disposed within the housing to produce a control emission signal in response to the excitation signal.

- 10 The reader and the assay device may be separable components. The assay device for example may be disposable after a single use while the reader may be reusable using a fresh assay device for each reading.
- 15 Alternatively, the reader and the assay device may be non-separable and both elements may be disposable after a single use.

Preferably, the assay reader has dimensions suitable for hand-held operation and convenient storage.

An assay device suitable for use in combination with a reader as described herein may include any device which produces a luminescent, preferably fluorescent, signal which is modulated (i.e. increased or decreased) by the presence of analyte. Preferably, a signal is produced or increased in the presence of analyte, for example through a sandwich assay format, although other arrangements are also possible, for example a competition assay format.

- 30 The principles and practice of fluorescence based immunoassays is well known in the art and various examples are commercially available, including Ramp<sup>TM</sup> (Response Biomedical, Burnaby Canada) and Biosite Triage<sup>TM</sup> (Biosite, San Diego CA).

Suitable assay devices for use with a reader of the invention include lateral flow immunoassay devices and homogenous assay devices.

5

In a lateral flow immunoassay in the 'sandwich' format, the presence of sufficient analyte in a sample will cause the formation of a 'sandwich' interaction at the capture zone in the lateral flow assay, whereby the polystyrene  
10 microspheres loaded with a fluorescent dye of choice become immobilised. Therefore, when the assay device held in the reading position and the light source is switched on, visible fluorescence is emitted. When sufficient particles are bound, the emitted light will be visible to  
15 the naked eye.

In a homogeneous assay device, sample is added directly to reagents which include a luminescent label in a reaction chamber. The presence of analyte in the sample  
20 increases or reduces the amount of label in the chamber which is able to luminescence in response to excitation. Examples of homogenous assay systems include molecular beacons (Tyagi & Kramer (1996) Nat. Biotechnol. 14 303-318).

25

Another aspect of the invention provides an assay apparatus comprising an assay reader as described above and one or more assay devices.

30 As described above, suitable assay devices produce a luminescent, preferably fluorescent, signal which is modulated (i.e. increased or decreased) by the presence of analyte. Such devices are well known in the art.

Suitable assay devices may comprise a capture zone which contains capture reagents such as antibody molecules, antigens, nucleic acids, lectins, and enzymes suitable for capturing a label. A device may also incorporate one  
5 or more luminescent labels suitable for capture in the capture zone, the extent of capture being determined by the presence of analyte. Suitable labels include fluorescent labels immobilised in polystyrene microspheres. Microspheres may be coated with  
10 immunoglobulins to allow capture in the capture zone. Other suitable labels include quantum dots and up-converting phosphor containing ceramic particles.

Another aspect of the invention provides a method of  
15 determining the presence of a luminescent label in the capture zone of an assay device comprising,  
exciting said label with an excitation signal of a first wavelength such that the excited label produces an emission signal of a second wavelength, and;  
20 visually observing the emission signal.

A method may further comprise filtering said excitation signal from said emission signal prior to observing said emission signal.

25 Another aspect of the invention provides a method of determining the presence of an analyte in a sample comprising;  
providing an assay device which comprises a luminescent  
30 label and a capture zone,  
contacting said device with a sample suspected of containing an analyte;

such that the amount of label captured in the capture zone is altered in the presence of said analyte in the sample relative to the absence of analyte in the sample,

exciting label captured in said capture zone with an  
5 excitation signal of a first wavelength such that the excited label produces an emission signal of a second wavelength, and;

visually observing the emission signal.

10 Aspects of the present invention will now be illustrated with reference to the accompanying figures described below and experimental exemplification, by way of example and not limitation. Further aspects and embodiments will be apparent to those of ordinary skill in the art.

15 All documents mentioned in this specification are hereby incorporated herein by reference.

Figure 1 shows a perspective view of an assay reader  
20 according to one embodiment of the invention with an assay device in the reading position.

Figure 2 shows a cutaway perspective view of an assay reader according to one embodiment of the invention with  
25 an assay device in the reading position showing the housing interior.

Figure 3 shows a plan view of the interior of the housing.

30 Figure 4 shows an example of a circuit plan for an assay reader.

Figure 5 shows an example of current regulating  
35 circuitry.

Table 1 shows results obtained using a model hCG lateral flow sandwich assay using fluorescent microspheres and read using a prototype visual reader.

5

Table 2 shows results obtained using a model strep A lateral flow sandwich assay using fluorescent microspheres and read using a prototype visual reader.

## 10 Examples

Sandwich lateral flow assays were performed as described in EPO29114 using polystyrene microspheres (obtained from Duke Scientific Corporation, Palo Alto), inside which a fluorescent dye was immobilised. This dye is proprietary to Duke, but is based upon chelates of beta-diketones and the lanthanide metal ion europium III. Other lanthanide metal ions such as terbium III, samarium III and dysprosium III may also be employed. The betadiketones are selected to allow for maximal excitation at about 350nm. Emission is dictated by the europium ion, and is maximal at about 612nm.

20

### Preparation of microspheres

1 ml of 0.15% solids (w/v) polystyrene microspheres coated with antibody was prepared according to the following protocol.

25

Stock antibody, either Unipath mouse monoclonal 3299:4 anti-alpha hCG (human chorionic gonadotrophin - the hormone whose presence indicates that a woman is pregnant) or rabbit polyclonal anti-*Streptococcus A* (Biospecific), was diluted to the required working concentration in 10mM disodium tetra borate buffer, pH 8.6, with 0.1% sodium azide (w/v) as preservative. For

30

the anti-hCG antibody, this dilution was 100-120 :g/ml, and for the anti-*Streptococcus A* antibody, 50-70 :g/ml.

75:1 of stock polystyrene microspheres {at 2% solids w/v} were placed in the bottom of a round-bottomed microfuge tube {2ml size}. For the hCG assay, the microspheres were 190nm in size with europium III chelates incorporated at 10% (w/w), and for the *Streptococcus A* assay, the microspheres were 400nm in size with europium III chelates incorporated at 10% (w/w). The tube (containing the microspheres) was placed on a vortex mixer, low setting, and mixed gently.

While the microspheres were mixing, 925:1 of antibody solution was slowly added, and the microspheres / antibody mixture was kept mixing for at least 10 seconds after all of the antibody was added.

The microspheres/antibody mixture was then probe-sonicated as follows: the cleaned tip of a probe sonicator (MSE Soniprep 150) was placed into the microfuge tube to a depth of two thirds of the liquid. The probe sonicator was turned on and set to 6 micron amplitude for about 10 to 15 seconds, ensuring that the microspheres/antibody mixture was not frothing.

The tubes were then placed on an end-over mixer and placed in a subdued-lighting environment to incubate for 1 hour at room temperature. This ensures full passive coating of the microspheres with antibody. 15:1 of 200mg/ml BSA solution was then added to the microspheres/antibody mixture, and mixing was continued

for a further 30 minutes at room temperature using the end-over mixer, again in subdued lighting.

The tubes were then removed from the end-over mixer and  
 5 centrifuged at 13,000 rpm (MSE Micro Centaur) for 10  
 minutes (400nm-microsphere size) or 20 minutes (190nm-  
 microsphere size). The supernatant was discarded and the  
 microsphere pellet resuspended with 1 ml of 10mM disodium  
 tetra borate (pH 8.6 with 0.1% sodium azide {w/v} as  
 10 preservative) using pipetting action / sonication bath  
 {Grant XB2 Ultrasonic Bath) and vortexing. The  
 microsphere suspension was then probe-sonicated again as  
 above.

15 The microfuge tubes were then centrifuged again as above.  
 The supernatant was discarded and the microsphere pellet  
 resuspended using pipetting action/sonication bath and  
 vortexing with 1 ml storage buffer: 20% sucrose, 6.5% B  
 SA in 10mM disodium tetraborate, (pH 8.6 with 0.1% sodium  
 20 azide (w/v) as preservative). The microsphere suspension  
 was sonicated again as above and then stored at 4°C until  
 required for use.

#### Assay reader

25 A prototype assay reader (1) was made as shown in Figures  
 1 to 3 and as follows:

A Roithner Lasertechnik RL T370-110 UV emitter (7), a  
 330-Ohm resistor (9), a switching mechanism (10), and  
 30 three lithium-cell batteries (Panasonic CR1818 3V) (5)  
 were assembled and connected with wiring (11) according  
 to the circuit diagram shown in figure 4, and housed in a  
 plastic casing (4) suitable for holding the plastic  
 lateral flow assay carriers (3) employed in the

experimental work. Screw holes (8) for assembly of the casing (4) are shown in Figures 1 to 3.

The plastic casing (4) had a viewing window (2), which  
5 was covered with ultra-violet protective (supplied by Upland, CA) as commonly used in ultra-violet radiation blocking spectacles. When the plastic lateral flow assay carrier (3) was inserted into the prototype assay reader (1), a switch (10) was activated and the circuit  
10 completed.

Due to the design of the reader, the UV emitter (7) was positioned such that any immobilised microspheres (6) in the lateral flow assay, when assembled into the carrier  
15 (3), were directly aligned with the UV emitter (7). Therefore the fluorescent dye in the immobilised microspheres was excited, and when sufficient microspheres were immobilised the visible fluorescence could be observed through the UV-protected window (2).

#### hCG immunoassay

A model hCG lateral flow sandwich assay was set up. Liquid-conducting material, in this case nitrocellulose (Schliecher & Schuell, Unipath Code 500213) with a  
25 restricted zone of immobilised protein, in this case Unipath mouse monoclonal 3468:2 anti-beta hCG antibody, was prepared as detailed in EP0291194.

The nitrocellulose membrane was cut into strips 6mm wide  
30 and 45mm in length, the immobilised antibody being a 1 mm wide band at a distance of 10mm from the end of the strip. These strips were assembled onto rigs such that the immobilised band of antibody was 10mm from the bottom of each strip when held in a vertical position. Some

absorbent material, such as Schleicher & Schuell gel blotting paper, was held in place at the top of each strip to absorb excess liquid. At the base of each strip was applied a mixture of 2.5:1 of the anti-alpha hCG coated fluorescently-dyed polystyrene microspheres (at 5 0.15% solids w/v in storage buffer) and 25:1 of hCG solution: hCG from Sigma, dissolved in phosphate buffered saline, pH 7.4, with 0.1% ovalbumin (Sigma) and 0.1% sodium azide as preservative) and calibrated using an 10 AutoDELFIA assay for hCG.

When the microspheres/hCG solution was taken up by the nitrocellulose, a further 25:1 of hCG solution was added to the base of each strip. When all of the liquid was 15 taken up, the nitrocellulose was removed from the rig, assembled into plastic carriers and read using the prototype assay reader.

The results obtained from this experiment are shown in 20 Table 1 below. As can be seen, levels of hCG as low as 1.81 mIU/ml can be detected visually using a lateral flow assay with fluorescent microspheres and the prototype reader.

25 This compares favourably with commercially available hCG lateral flow sandwich assays, such as the Clear Blue Easy™ (Unipath Ltd.) pregnancy test kit, with a lower detection limit of 50 mIU/ml, and the First Response Early Result™ (Carter-Wallace Inc) pregnancy test kit, 30 which has a similar detection limit of about 50 mIU/ml.

#### Streptococcus A Immunoassay

A standard immunoassay for *Streptococcus A* specific antigen would normally begin by performing an extraction

procedure on a throat swab sample to release the Group A specific carbohydrate antigen from the peptidoglycan cell wall of the bacteria. This extraction procedure can be performed by placing the throat swabs into a 1:1 mixture  
5 of 1M acetic acid and 1M sodium nitrite (320:1 total volume). Mixing these two chemicals produces nitrous acid (an instable acid) which cleaves the *Streptococcus A* specific antigen from the bacterial cell wall. After about 2 minutes, 160:1 of a neutralising reagent,  
10 typically 1.6M Tris Base, can be added and a lateral flow assay performed on the neutralised cell extract.

A model assay system for the detection of *Streptococcus A* specific was performed by substituting 20:1 volumes of  
15 standards of the purified *Streptococcus A* specific carbohydrate antigen for the throat swab, and carrying out the rest of the procedure (to mimic the real assay). The standards (Unipath, in-house) were prepared to give antigen levels equivalent to known numbers of cells in a  
20 suspension (cfu or colony forming units per ml).

Liquid-conducting material, in this case nitrocellulose (Schliecher & Schuell, Unipath Code 500226) with a restricted zone of immobilised protein, in this case  
25 rabbit polyclonal G47010145 anti-Strep. A antibody (BiosPacific), was prepared as detailed in EP0291194.

The nitrocellulose membrane was cut into strips 6mm wide and 45mm in length, the immobilised antibody being a 1mm  
30 wide band at a distance of 10mm from the end of the strip. These strips were assembled onto rigs such that the immobilised band of antibody was 10mm from the bottom of each strip when held in a vertical position. Some absorbent material, such as Schliecher & Schuell gel

blotting paper, was held in place at the top of each strip to absorb excess liquid. At the base of each strip was applied a mixture of 2.5:1 of *anti-Strep*. A antibody coated fluorescently-dyed polystyrene microspheres (at 5 0.075% solids w/v in storage buffer) and 25:1 of the neutralised cell extract. When the microspheres/cell extract solution was taken up by the nitrocellulose, a further 25:1 of cell extract solution was added to the base of each strip. When all of the liquid was taken up, 10 the nitrocellulose was removed from the rig, assembled into plastic carriers and read using the prototype assay reader.

The results from this experiment are shown in Table 2.

15 As can be seen, the lowest detectable level of *Streptococcus A* specific antigen was that present in standard antigen preparation 5. This is equivalent to the amount of antigen one would expect to detect from 20:1 of 20 a  $7.5 \times 10^5$  cfu/ml cell suspension. As only 20:1 of standard was used in the experiment, then the test has detected the equivalent of  $1.5 \times 10^4$  cfu.

This compares favourably with commercially available 25 lateral flow assays for *Streptococcus A* based on the detection of the carbohydrate antigen. QuickVue Flex<sup>TM</sup> lateral flow *Strep. A* test (Quidel, San Diego, CA) detects about  $5 \times 10^5$  cfu or *Streptococcus A* organisms from a throat swab and *Strep. A* OIA MAX<sup>TM</sup> optical 30 immunoassay ThermoBiostar, Boulder, CO) detects  $1.2 \times 10^4$  cfu from a throat swab - although this is not a lateral flow system, this is most sensitive immunoassay

commercially available for the detection of *Streptococcus* A.

5 The prototype assay reader system allows for a 30-fold improvement over other lateral flow devices in the detection of *Streptococcus* A through the presence of the carbohydrate antigen.

Standard	[hCG] mIU/ml	Visible result: Rep 1	Visible result: Rep 2	Visible result: Rep 3
1	0.027	No	No	No
2	0.09	No	No	No
3	0.14	No	No	No
4	0.41	No	No	No
5	0.91	No	No	No
6	1.81	Yes	Yes	Yes
7	3.6	Yes	Yes	Yes
8	7.67	Yes	Yes	Yes
9	15.0	Yes	Yes	Yes
10	59.1	Yes	Yes	Yes

Table 1

Throat swab	Equivalent cfu/ml	Visible result: Rep 1	Visible result: Rep 2
1	$2.5 \times 10^7$	Yes	Yes
2	$6.25 \times 10^6$	Yes	Yes
3	$3 \times 10^6$	Yes	Yes
4	$1.5 \times 10^6$	Yes	Yes
5	$7.5 \times 10^5$	Yes	Yes
6	$3.75 \times 10^5$	No	No
7	0	No	No

Table 2

Claims:

1. An assay reader for determining the presence of a  
5 luminescent label in the capture zone of an assay device comprising,

a positioning member to hold the assay device in a reading position,

10 a light source which produces an excitation signal for exciting luminescent label in said capture zone when said assay member is in the reading position, and;

a viewing window for direct observation of the luminescent emission signal from said label in said capture zone.

15

2. An assay reader according to claim 1 wherein said light source is contained in a housing, the housing further containing the assay device when in the reading position,

20

the viewing window being positioned in the housing so as to provide for direct observation of the emission signal from label in the capture zone of the device.

25

3. An assay reader according to claim 1 or claim 2 wherein the wavelength of the excitation signal is different from the wavelength of the emission signal.

30

4. An assay reader according to claim 3 wherein the wavelength of the excitation signal is greater than the wavelength of the emission signal.

5. An assay reader according to claim 3 wherein the wavelength of the excitation signal is less than the wavelength of the emission signal.

6. An assay reader according to any one of claims 3 to 5 comprising a filter which blocks the passage of the excitation signal and allows the passage of the emission  
5 signal through the viewing window.

7. An assay reader according to claim 6 wherein said filter is located on said window.

10 8. An assay reader according to claim 7 wherein said filter is located in said assay device.

9. An assay reader according to any one of claims 1 to 8 for determining the presence of a first and a second  
15 luminescent label in said capture zone,

said reader comprising a first filter which blocks the passage of the first emission signal from the first label and a second filter which blocks passage of a second emission signal from a second luminescent label.

20

10. A assay reader according to claim 9 wherein the first and second filters are switchable between a first configuration, in which the first filter is positioned at said viewing window and a second configuration, in which  
25 the second filter is positioned at said viewing window.

11. A assay reader according to claim 9 wherein the first filter is positioned at a first viewing window and the second filter is positioned at a second viewing window.

30

12. An assay reader according to any one of claims 1 to 8 for determining the presence of a first and a second luminescent label in said capture zone,

said reader comprising a first light source which produces a first excitation signal for exciting the first luminescent label and a second light source which produces a second excitation signal for exciting the  
5 second luminescent label.

13. A assay reader according to claim 12 wherein the first and second light sources are switchable between a first mode, in which the first excitation signal is  
10 produced without the second excitation signal, and a second mode, in which the second excitation signal is produced without the first excitation signal.

14. An assay reader according to any one of claims 9 to  
15 13 adapted to determine the presence of three or more labels in the capture zone.

15. A assay reader according to any one of claims 2 to  
20 14 wherein said window comprises an aperture in said housing.

16. A assay reader according to any one of claims 2 to  
25 14 wherein said housing defines a recess and said window comprises the mouth of the recess.

17. A assay reader according to any one of claims 1 to  
16 wherein said window comprises a lens.

18. A assay reader according to claim 17 wherein said  
30 lens is shaped to adapt the image in said window.

19. A assay reader according to claim 18 wherein said lens is shaped to magnify the image in said window.

20. An assay reader according to claim 18 for determining the presence of a first and a second luminescent label in said capture zone, wherein emission from the first label is adapted into a first shape and  
5 emission from the second label is adapted into a second shape.

21. An assay reader according to any one of the preceding claims wherein said window comprises a non-  
10 reflective surface.

22. An assay reader according to any one of the preceding claims wherein said luminescent label is a fluorescent label and said emission signal is a fluorescent emission  
15 signal.

23. An assay reader according to any one of the preceding claims wherein said light source is an ultra-violet light source and said excitation signal is ultra-violet light.  
20

24. An assay reader according to any one of the preceding claims comprising a battery connected to said light source.

25. An assay reader according to any one of the preceding claims comprising circuitry adapted to power light source in the presence of liquid in said assay device.

30 26. An assay reader according to any one of the preceding claims comprising circuitry to provide a fixed current from said battery.

27. An assay reader according to any one of the preceding claims wherein the reader and the assay device are separable

5 28. An assay reader according to any one of the preceding claims herein the reader and the assay device are non-separable.

10 29. An assay reader according to any one of the preceding claims comprising a control indicator to indicate sufficient battery power to generate the excitation signal.

15 30. An assay reader according to claim 29 wherein said control indicator is an LED indicator on an outer surface of said reader.

20 31. An assay reader according to claim 29 wherein said control indicator is an electrochromic or thermochromic indicator on an outer surface of said reader.

25 32. An assay reader according to claim 29 wherein said control indicator is a fluorescent dye which produces a control emission signal in response to the excitation signal.

30 33. An assay reader according to any one of the preceding claims wherein the assay device is lateral flow immunoassay device

34. An assay reader according to any one of the preceding claims wherein the assay device is a homogenous assay device.

35. An assay apparatus comprising an assay reader according to any one of claims 1 to 34 and one or more assay devices.

5 36. An assay apparatus according to claim 35 wherein said one or more assay devices comprise a capture zone and one or more luminescent labels.

37. A method of determining the presence of a  
10 luminescent label in the capture zone of an assay device comprising,

exciting said label with an excitation signal of a first wavelength such that the excited label produces an emission signal of a second wavelength, and;  
15 visually observing the emission signal.

38. A method according to claim 37 comprising filtering said excitation signal from said emission signal prior to observing said emission signal.

20

39. A method according to claim 37 or claim 38 wherein the label is selected from the group consisting of a fluorescent label immobilised in a polystyrene microsphere, a quantum dot and an up-converting phosphor  
25 containing ceramic microsphere.

40. A method of determining the presence of an analyte in a sample comprising;  
providing an assay device which comprises a luminescent  
30 label and a capture zone,  
contacting said device with a sample suspected of containing an analyte;

such that the amount of label captured in the capture zone is altered in the presence relative to the absence of analyte in the sample,

exciting label captured in said capture zone with an  
5 excitation signal of a first wavelength such that the excited label produces an emission signal of a second wavelength, and;

visually observing the emission signal.




Figure 1

**THIS PAGE BLANK (USPTO)**




Figure 2

**THIS PAGE BLANK (USPTO)**




Figure 3

**THIS PAGE BLANK (USPTO)**




Figure 4

THIS PAGE BLANK (USPTO)




Figure 5

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**